Title: HexAgon-HN: Phase 2/3 Study of the Hexavalent OX40 Agonist INBRX-106 as an Add-On to Pembrolizumab in First-Line Recurrent/Metastatic PD-L1+ (Combined Positive Score ≥20) Head and Neck Cancer
Lead Author: Dan P. Zandberg
Abstract: 651
Location: George R. Brown Convention Center, Houston, TX - Level 1 – Exhibit Halls AB
Trial-in-progress poster presentation on Friday, November 8, 2024 from 12:15-1:45 PM CST and 5:30-7:00 PM CST
Title: CD8+ T cells play a critical role in novel hexavalent OX40 agonist treatment to favor anti-tumor immunity
Lead Author: Nisha Holay
Abstract: 1301
Location: George R. Brown Convention Center, Houston, TX - Level 1 – Exhibit Halls AB
Poster presentation on Friday, November 8, 2024 from 12:15-1:45 PM CST and 5:30-7:00 PM CST
